FDA, CDC experts: What physicians need to know about tecovirimat (TPOXX) for treatment of monkeypox, Part 2

Experts from the FDA and CDC continue their discussion on tecovirimat, or TPOXX, for the treatment of monkeypox in infected individuals. In part two of this mini-series, experts answer physicians' questions about treatment for monkeypox. Guests include Adam Sherwat, MD, Deputy Director, Office of Infectious Disease at FDA’s Center for Drug Evaluation and Research; Brett W. Petersen, MD, MPH, Deputy Chief, Poxvirus and Rabies Branch, CDC’s Division of High-Consequence Pathogens and Pathology; and Timothy Wilkin, MD, MPH, Professor of Medicine and Assistant Dean for Clinical Research Compliance for Human Research Protections at Weill Cornell Medicine and TPOXX clinical trial lead.     ⭐⭐⭐⭐⭐ 🩺 The AMA is your powerful ally, focused on addressing the issues important to you, so you can focus on what matters most — patients. We will meet this challenge together. Join us: https://ama-assn.co/JoinRenew  🥼 Go to https://ama-assn.co/FightingForDocs to learn more about our AMA advocacy priorities, including:  ▹ Reforming Medicare payment  ▹ Fighting scope creep  ▹ Fixing prior authorization  ▹ Reducing physician burnout  ▹ Making technology work for physicians  📺 Subscribe to @americanmedicalassociation on YouTube: https://ama-assn.co/youTube  📧 Sign up for #MorningRounds and free daily newsletters from the AMA: https://ama-assn.co/Newsletters  💬 Follow #AMA on social media: https://ama-assn.co/Social